Minimally invasive surgical approaches are not only here to stay in
spinal care, they are likely to continue growing as a percentage of
overall cases. That's great news for NuVasive (NASDAQ:NUVA),
as is progress toward the sort of operating margins that would normally
be expected of a quality med-tech company. While a failure to get clean
operating margins above 20% looms as a long-term risk for this company,
as does competition, the ongoing consolidation in the orthopedics space
may well make that somebody else's problem. I'm always a little leery
of jumping into a story that is already up 50% over the past year, but I
can't rule out the potential upside as investors covet growth stories
in med-tech with an M&A angle.
Please read more here:
NuVasive Running On Renewed MIS Vigor
No comments:
Post a Comment